UDCA (ursodiol) / TUDCA for healthspan and lifespan?

I can’t be more convinced that making stuff up is his forte.

2 Likes

There’s no down side that I know of and I take it and my wife and several friends. But I can say that there’s a difference between brands and I wish I knew somebody that tested them all and could tell us which one is best. Some barely work at all.

Thanks for that @Bicep…. *adds to cart.

I just AI’d and I see Vitality Pro offers it. I could be wrong but it’s my impression they are one of the highest quality brands. Edit: I now see Adssx mentioned them which is probably why I knew it’s a good brand.

At some point I just got it in my head that UK brands are generally of higher quality than the US, but this might not be accurate!

Edit: @Bicep I see @Davin8r uses Nootropics and he is usually pretty good at sourcing. Nootropics is same cost per pill but nootropics is 500mg vs VP at 250mg

When they fill capsules the dust gets on the outside in small amounts. It’s unavoidable. My wife says if they taste like bile (which is awful) then they work. She needs it for her gall bladder. We are currently using Bulk Supplements brand and it does taste bad. It’s cheapest on rapadmin’s list too.

1 Like

@Bicep Excellent feedback. I’ll now reach out to Nootropics and Vitality Pro to confirm they have zero residue on their capsules and zero taste… I’ll be back to share what I learn.

I had my gallbladder taken out which was one of the best things to happen to me… . Undiagnosed for many years and felt awful… turns out it was gangrene… lovely!

Glad it’s helping your wife, but if she ever needed the surgery, I’ll share that for me, it was a big nothing…. And I’m even too wimpy to take an icky tasting supplement :slight_smile:

Transmissible gastroenteritis virus in pigs :pig: : Ursodeoxycholic acid against TGEV infection via the JAK-STAT1 signaling pathway 2026

Clinical effects of ursodeoxycholic acid in COVID-19 infection: A systematic review and dose-response meta-analysis 2026: “UDCA showed association with a lower risk of infection (OR,0.69;95%CI,0.55-0.86). And UDCA associated with lower severe infection risk (OR,0.75;95%CI,0.64-0.89), and ventilator use (OR,0.75;95%CI,0.62-0.90) compared to controls.”

On the other hand: Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19: A Randomized Clinical Trial 2026: “A 2-week course of metformin or UDCA did not significantly improve recovery from PASC.”

Bile Acids as Candidate Therapies for Multiple Sclerosis: Inverse Signal Analysis Using the FDA Adverse Event Reporting System and Preclinical Validation 2026: “Inverse associations were identified for UDCA (odds ratio [OR]: 0.197, 95% confidence interval [CI]: 0.117–0.333) […] In the EAE model, UDCA was associated with lower clinical scores at the peak (day 18) and late phases (days 26–28)”

1 Like

This was wrong, see update here: Ora Biomedical Million Molecule Challenge Results - #466 by adssx

1 Like

Thanks for the update! I stopped taking TUDCA because of your previous findings (I am 34 so I prefer to reduce risks as much as possible) even if my biomarkers improve a lot with it. These new results are encouraging.

So, besides stopping if you have cancer due to its anti-apoptotic effect or if you feel is causing intestinal distress… we don’t have many issues with it?

1 Like

Ursodeoxycholic acid treatment did not show protective effect for severe COVID-19 outcomes – a nationwide register study 2026

This study did not provide evidence supporting protective effects for severe COVID-19 outcomes. However, the results are limited by the small cohort of patients treated with UDCA.

TUDCA treatment restores aortic and perivascular adipose tissue function in post-weaning protein-restricted mice 2026

Post-weaning protein restriction induces vascular and PVAT dysfunction and fibrosis in males, associated with ER stress. TUDCA significantly attenuates these alterations, supporting its potential as a therapeutic strategy for vascular complications associated with early-life undernutrition.

Network pharmacology-based discovery and experimental validation of novel drug repurposing candidates in Alzheimer’s Disease 2026

Preprint but NIA

A network pharmacology approach identified TUDCA and arundine as promising repurposing candidates in AD that rescue disease-relevant molecular phenotypes by acting on AD-associated genes through regulation of G protein signaling.